Our Mentors

Dr. Fogarty was fortunate to have had wise mentors guiding him throughout his career, which resulted in his ability to save the lives and limbs of over 20 million patients. As he has famously stated, "I certainly wouldn't be where I am today if it wasn't for the concept of mentorship, which I believe is critically important for innovation."

Here at the Institute, we understand that mentors are crucial to the success of any innovator. That's why we not only have a mentorship program for our companies-in-residence, but also for young students who show a passion for medical innovation.

Throughout the years, we have had the privilege of forging relationships with some of the best-known names in the medical device industry, who are helping pave the way for our interns and startups. Our mentors include:

Hanson Gifford, Managing Partner, The Foundry, LLC

Mr. Gifford co-founded The Foundry in 1998. His key activities include inventing and identifying new technologies, and forming, financing, staffing, and providing ongoing support for The Foundry's new companies. Prior to The Foundry, Mr. Gifford was VP of R&D at Heartport. Mr. Gifford is a co-inventor on over 225 issued US patents. He earned his B.S. degree in mechanical engineering from Cornell University. Mr. Gifford serves as Chairman of Forsight Labs, and is a Director of Miramar Labs, Twelve, Cotera, FIRE1, Forsight Vision 4 and Forsight Vision 5. He is also a Venture Partner with Lightstone Ventures.

Angela Macfarlane, President & CEO, ForSight Labs

Ms. Macfarlane joined ForSight Labs as President and CEO in March of 2007. Ms. Macfarlane brings broad experience in early stage company formation to ForSight Labs with the goal of creating a community where innovation, creative solutions and "the doing" are combined to build value and create companies focused on improving the lives of visually impaired patients. Prior to joining the ForSight Labs team full-time, Ms. Macfarlane served as Chief Technology Counsel to The Foundry and participated on the ForSight Labs senior management team through her role at The Foundry, as well as working with early stage Foundry start ups. Ms. Macfarlane participates on the board of the ForSight VISIONSM companies. She is an inventor on three U.S. issued patents with others currently pending.

Josh Makower, General Partner, New Enterprise Associates, Inc.

Josh joined NEA in September 2004 as a Venture Partner but has worked closely with NEA since his time as an NEA EIR back in 1995. He is currently a General Partner on NEA's healthcare team and focuses primarily on medical devices and consumer health technologies. Josh is also the Founder & Chief Executive Officer of ExploraMed I, II, III, and IV Inc., a series of NEA portfolio medical device incubators based on the West Coast that have created eight companies over the past 20 years. Josh also serves a part-time role on the faculty of the Stanford University Medical School as a Consulting Professor of Medicine and is Co-Founder of Stanford's Biodesign Innovation Program. Josh serves on the board of directors for ExploraMed II, III and IV, Intrinsic Therapeutics, Inc., NeoTract, Inc., Moximed, Inc., Ceterix, Inc., Nuelle, Inc, NC7 Inc. and Coravin. Josh holds over 100 patents for various medical devices in the fields of cardiology, ENT, general surgery, drug delivery, obesity, orthopedics, women's health and urology.

Hank Plain, Partner, Morgenthaler Ventures, Life Science Team; General Partner, Lightstone Ventures

Hank is a General Partner of Lightstone Ventures. He focuses on medical device investments out of the firm's Menlo Park office. Hank also serves as a General Partner at Morgenthaler Ventures which he joined in 2007 after more than 25 years in the life science industry. Prior to becoming a venture capitalist, he co-founded eight medical device companies. He has served as a director for eight companies that have had successful exits with a combined value in excess of $3 billion. In May 2014, Cardinal Health completed the acquisition of Access Closure for $320 million. In June 2014, Ulthera, Inc. acquired Cabochon Aesthetics in cash and milestone payments. Hank served as a board member of both companies.

In 2011, Medtronic completed the acquisition of Ardian for $800 million, plus annual revenue growth milestones through Medtronic's fiscal 2015. Hank was a founder, helped incubate Ardian while at The Foundry, and served as a Director of the company.